Wogonoside alleviates hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells via PI3K/AKT signaling - Summary - MDSpire

Wogonoside alleviates hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells via PI3K/AKT signaling

  • By

  • Yuan Zhong

  • Jian Shi

  • Xi Long

  • Xiyuan Liu

  • Lihao Chen

  • Jun Peng

  • Qinghua Peng

  • May 4, 2026

  • 0 min

Share

Objective:

To investigate the protective effects of Wogonoside (WGS) against hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells, highlighting its potential significance in dry eye treatment and elucidating the underlying mechanisms involving the PI3K/AKT pathway.

Approach:
    Key Findings:
    • 203 overlapping targets were identified between WGS-related and dry eye-related target sets, indicating a significant interaction.
    • PI3K/AKT signaling was highlighted as a relevant pathway, with specific emphasis on its role in cell survival.
    • WGS improved cell viability by X%, reduced apoptosis by Y%, and decreased inflammatory mediator levels in hyperosmotic HCE-T cells.
    • The protective effects of WGS were associated with the restoration of PI3K/AKT signaling, suggesting a direct mechanism of action.
    Interpretation:

    Wogonoside exhibits protective effects against hyperosmotic stress in corneal epithelial cells, primarily through the modulation of the PI3K/AKT signaling pathway, suggesting its potential as a therapeutic candidate for dry eye-related injuries, warranting further clinical exploration.

    Limitations:
    • The study primarily utilized in vitro models, which may not fully replicate in vivo conditions; potential confounding factors should be considered.
    • Further validation in animal models of dry eye is necessary to confirm the translational potential of the findings.
    Conclusion:

    Wogonoside shows promise in alleviating hyperosmotic stress-induced epithelial injury, warranting further investigation in clinical settings to validate its therapeutic potential.

Original Source(s)

Related Content